Search results for "Aminolevulinic Acid"

showing 10 items of 17 documents

Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy for Healthy Human Skin.

2015

Peer reviewed

0301 basic medicineAdultmedicine.medical_specialtyTime Factorsmedicine.medical_treatmenteducationPain5-AMINOLEVULINIC ACIDHuman skinPhotodynamic therapyPilot ProjectsEUROPEAN GUIDELINESDermatology030105 genetics & heredityAdministration Cutaneousphotodynamic therapy (PDT)ihosyöpä03 medical and health sciencesDouble-Blind MethodMedicineHumansPhotosensitizerProdrugsSkinACTINIC KERATOSESihoPhotosensitizing Agentsbusiness.industryGeneral MedicineActinic keratosesAminolevulinic AcidDermatologyHealthy Volunteers3. Good healthOikeuslääketiede ja muut lääketieteet - Forensic science and other medical sciencesREDUCES INFLAMMATIONPhotochemotherapyErythema3121 General medicine internal medicine and other clinical medicinebusinessActa dermato-venereologica
researchProduct

Clinical Guide and Update on Porphyrias.

2019

Physicians should be aware of porphyrias, which could be responsible for unexplained gastrointestinal, neurologic, or skin disorders. Despite their relative rarity and complexity, most porphyrias can be easily defined and diagnosed. They are caused by well-characterized enzyme defects in the complex heme biosynthetic pathway and are divided into categories of acute vs non-acute or hepatic vs erythropoietic porphyrias. Acute hepatic porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) manifest in attacks and are characterized by overproduction of porphyrin precursors, producing often serious abdomin…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPorphyrinsGastrointestinal DiseasesVariegate porphyriaPorphobilinogenCongenital erythropoietic porphyriaGastroenterologySkin Diseases03 medical and health sciencesPorphyrias0302 clinical medicineInternal medicinemedicineHumansPorphyria cutanea tardaskin and connective tissue diseasesAcute intermittent porphyriaHepatologybusiness.industryHepatoerythropoietic porphyriaGastroenterologynutritional and metabolic diseasesAminolevulinic Acidmedicine.disease030104 developmental biologyHereditary coproporphyriaPorphyriaPractice Guidelines as Topic030211 gastroenterology & hepatologyErythropoietic protoporphyriaNervous System DiseasesbusinessGastroenterology
researchProduct

Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery.

2006

To overcome the limited treatment depth of superficial photodynamic therapy we investigate interstitial light delivery. In the present work the treatment light was delivered using a system in which three or six clear-cut fibers were placed in direct contact with the tumor area. This placement was thought to represent a step toward general purpose interstitial PDT. Twelve nodular basal cell carcinomas were treated employing delta-aminolevulinic acid and 635 nm laser irradiation. Fluorescence measurements were performed monitoring the buildup and subsequent bleaching of the produced sensitizer protoporphyrin IX. The treatment efficacy, judged at a 28-month follow-up, showed a 100% complete re…

AdultMalePathologymedicine.medical_specialtySkin NeoplasmsHealth Toxicology and Mutagenesismedicine.medical_treatmentNodular basal cell carcinomaProtoporphyrinsPhotodynamic therapyToxicologyLight deliveryFluorescencePathology and Forensic Medicinechemistry.chemical_compoundCarcinomamedicineHumansComplete responseAgedPhotosensitizing AgentsProtoporphyrin IXbusiness.industryLasersGeneral MedicineAminolevulinic AcidMiddle Agedmedicine.diseaseTreatment efficacyGeneral purposechemistryPhotochemotherapyCarcinoma Basal CellFemalebusinessNuclear medicineJournal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
researchProduct

Intensified oxidative and nitrosative stress following combined ALA-based photodynamic therapy and local hyperthermia in rat tumors.

2003

Oxidative stress-related changes in tumors upon localized hyperthermia (HT), 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) and their combination (ALA+HT) were examined after the observation that the antitumor effects of ALA-PDT could be significantly enhanced upon simultaneous application of HT. Rats bearing s.c. DS-sarcomas (0.6–1.0 ml) on the hind foot dorsum were anesthetized and underwent one of the following treatments: (i) ALA-PDT (375 mg/kg 5-ALA i.v.); (ii) localized HT, 43°C for 60 min; (iii) combined ALA-PDT and HT [=ALA+HT]. Appropriate control experiments were also performed. After treatment, tumors were excised and rapidly frozen for later analysis of nitrosative s…

HyperthermiaMaleCancer ResearchLightNitrosationApoptosisPharmacologymedicine.disease_causeRats Sprague-Dawleychemistry.chemical_compoundIn vivoHeat shock proteinmedicineAnimalsHSP70 Heat-Shock ProteinsHeat-Shock Proteinschemistry.chemical_classificationGlutathione PeroxidasePhotosensitizing AgentsGlutathione peroxidaseSarcomaGlutathioneAminolevulinic Acidmedicine.diseaseGlutathioneHsp70RatsGene Expression Regulation NeoplasticOncologyBiochemistrychemistryPhotochemotherapyApoptosisHeme Oxygenase (Decyclizing)OxygenasesOxidative stressCell DivisionHeme Oxygenase-1International journal of cancer
researchProduct

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours.

2003

The possibility of enhancing aminolaevulinic acid (ALA)-based photodynamic therapy (PDT) by simultaneous application of localised hyperthermia (HT) was evaluated. Treatments of rat DS-sarcomas included: (i) control, (ii) ALA administration (375 mg kg(-1), i.p.), no illumination, (iii) 'nonthermal' illumination, (iv) ALA-PDT: that is, ALA administration, 'nonthermal' illumination, (v) localised HT, 43 degrees C, 60 min (vi) ALA-PDT+HT: ALA administration with full spectrum irradiation resulting in ALA-PDT and HT. Tumour volume was monitored for 90 days or until a target volume (3.5 ml) was reached. No differences were seen between the first three groups, with all tumours reaching the target …

HyperthermiaMaleCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentPlanning target volumePhotodynamic therapyPharmacologyRats Sprague-DawleymedicineAnimalsPhotosensitizerExperimental TherapeuticsPhotosensitizing AgentsCell Deathbusiness.industryAminolaevulinic acidSarcomaAminolevulinic AcidHyperthermia Inducedmedicine.diseasehyperthermia5-aminolaevulinic acidIn vitroRatsDisease Models Animalrat sarcomaTreatment OutcomeOncologyPhotochemotherapyphotodynamic therapyLocal Hyperthermiainfrared-A-radiationSarcomabusinessBritish journal of cancer
researchProduct

Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid.

2003

Abstract Background/Aims : 5-Aminolevulinic acid (ALA), a precursor of porphyrins is used for photodynamic diagnosis and therapy within topical or systemic applications. A potential toxic effect on the human liver is of major interest and therefore we investigated the impact of a repeated application of ALA without illumination on cultures of human hepatocytes. Methods : After ALA treatment of hepatocytes in vitro the porphyrin synthesis, albumin secretion, liver-specific enzyme release, and malondialdehyde levels were determined. In order to reduce levels of reactive oxygen substances, mannitol and the antioxidant enzymes superoxide dismutase and catalase were supplemented. Results : Porph…

MaleAntioxidantPorphyrinsCell Survivalmedicine.medical_treatmentIn Vitro TechniquesAntioxidantsLipid peroxidationSuperoxide dismutasechemistry.chemical_compoundmedicineHumansCells Culturedchemistry.chemical_classificationPhotosensitizing AgentsHepatologyProtoporphyrin IXbiologyDose-Response Relationship DrugSuperoxide DismutaseAlbuminAminolevulinic AcidMalondialdehydeEnzymeBiochemistrychemistryCatalasebiology.proteinHepatocytesLipid PeroxidationReactive Oxygen SpeciesJournal of hepatology
researchProduct

Effect of unbalanced diets on incorporation of δ-aminolevulinic acid into cytochrome P-450

1987

Abstract The in vivo syntheses of two liver microsomal cytochromes P-450 PB 3a , P-450 UT 50 [(1987) Eur. J. Biochem., submitted] ( M r 50 000, 52 000) have been estimated by measuring the specific activity 2 h after i.p. administration of δ-[ 3 H]aminolevulinic acid to male Sprague Dawley rats. The animals were fed either a standard rat chow (5% lard, 22% casein) or unbalanced diets (high lipid, 30% lard or low protein, 6% casein) with or without 50 ppm Phenoclor DP6. The high-lipid diet supported a more rapid body weight gain but had little impact on cytochrome P-450 content, expressed either per whole liver or per mg microsomal protein, and on the incorporation of the precursor into cyto…

MaleDietary proteinLow proteinCytochromeBiophysicsPolychlorobiphenylBiochemistryIsozymeδ-Aminolevulinic acidchemistry.chemical_compoundCytochrome P-450 Enzyme SystemNutritional effectStructural BiologyIn vivoCaseinGeneticsAnimalsCelluloseMolecular BiologyChromatographybiologyRats Inbred StrainsAminolevulinic AcidCell BiologyLevulinic AcidsDietRatsLiverchemistryBiochemistryCytochrome P-450 synthesisMicrosomebiology.proteinSpecific activityFEBS Letters
researchProduct

Ablative fractional laser-assisted photodynamic therapy for lentigo maligna: a prospective pilot study.

2019

Background Lentigo maligna (LM) is an in‐situ form of melanoma carrying a risk of progression to invasive lentigo maligna melanoma (LMM). LM poses a clinical challenge, with subclinical extension and high recurrence rates after incomplete surgery. Alternative treatment methods have been investigated with varying results. Photodynamic therapy (PDT) with methylaminolaevulinate (MAL) has already proved promising in this respect. Objectives To investigate the efficacy of ablative fractional laser (AFL)‐assisted PDT with 5‐aminolaevulinic acid nanoemulsion (BF‐200 ALA) for treating LM. Methods In this non‐sponsored, prospective pilot study ten histologically verified LMs were treated with AFL‐as…

Malemedicine.medical_specialtyBF-200 ALASkin NeoplasmsBiolääketieteet - Biomedicinemedicine.medical_treatmentFractional laserPhotodynamic therapyPilot ProjectsDermatologyLentigo malignalaserhoitoHutchinson's Melanotic Freckle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineablative fractional laser5-aminolaevulinic acid nanoemulsionAblative casemedicineHumansmelanoomaProspective StudiesLentigo maligna melanomaSubclinical infectionAgedAged 80 and overbusiness.industryRopivacaineMelanomaSisätaudit - Internal medicineAminolevulinic AcidMiddle Agedmedicine.diseaseCombined Modality Therapy3. Good healthInfectious Diseasesphotodynamic therapyfotodynaaminen hoitoPhotochemotherapy030220 oncology & carcinogenesisFemaleRadiologyLaser Therapylentigo malignabusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the tre…

2018

Abstract Background The most effective treatment modality for actinic keratosis (AK) is photodynamic therapy (PDT). Major obstacles of PDT are the need of a special illumination device and pain accompanying the illumination. These issues may be overcome by replacing an artificial high‐power light source with natural daylight for more extended illumination at lower light doses. Objective To determine whether BF‐200 ALA (a nanoemulsion gel containing 7.8% 5‐aminolaevulinic acid) is non‐inferior to MAL (a cream containing 16% methyl‐aminolaevulinate) in the treatment of mild‐to‐moderate AK with daylight PDT (dPDT). Non‐inferiority of the primary efficacy variable (total lesion clearance rate p…

Malemedicine.medical_specialtyKeratosisgenetic structuresOriginal Articles and Short Reports Oncologymedicine.medical_treatmentUrologySkin CreamPhotodynamic therapyDermatologyAdministration CutaneousSeverity of Illness IndexStatistics Nonparametriclaw.inventionLesion030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanySeverity of illnessmedicineClinical endpointHumansAgedPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic Acidmedicine.diseasePrognosisClinical trialKeratosis ActinicInfectious DiseasesTreatment OutcomePhotochemotherapySpain030220 oncology & carcinogenesisFemaleOriginal Articlemedicine.symptombusinessGelsJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminol…

2018

Background: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC. Objective: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean …

Malemedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSkin CreamPhotodynamic therapyDermatologyAdministration Cutaneouslaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialMethyl aminolevulinatelawCarcinomaHumansMedicineBasal cell carcinomaAgedSkinPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic AcidMiddle Agedmedicine.diseaseDermatologyClinical trialTreatment OutcomePhotochemotherapyCarcinoma Basal Cell030220 oncology & carcinogenesisFemaleSkin cancerbusinessmedicine.drugBritish Journal of Dermatology
researchProduct